Natarajan Sethuraman
Chief Tech/Sci/R&D Officer at ENTRADA THERAPEUTICS, INC.
Net worth: 2 M $ as of 30/04/2024
Natarajan Sethuraman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2017 | - |
Career history of Natarajan Sethuraman
Former positions of Natarajan Sethuraman
| Companies | Position | Start | End |
|---|---|---|---|
| MERCK & CO., INC. | Director/Board Member | 01/08/2006 | 01/07/2016 |
| Corporate Officer/Principal | 01/08/2006 | 01/07/2016 | |
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG. Medical Enzymes business strategy focuses on the clinical development of therapeutic enzymes until clinical proof of concept and to commercialize those products through collaboration with selected pharmaceutical partners. | Corporate Officer/Principal | - | - |
Training of Natarajan Sethuraman
| Tamilnadu Agricultural University | Undergraduate Degree |
| Indian Agricultural Research Institute | Doctorate Degree |
Statistics
International
| United States | 3 |
| India | 3 |
| Germany | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ENTRADA THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Private companies | 1 |
|---|---|
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG. Medical Enzymes business strategy focuses on the clinical development of therapeutic enzymes until clinical proof of concept and to commercialize those products through collaboration with selected pharmaceutical partners. | Health Services |
- Stock Market
- Insiders
- Natarajan Sethuraman
- Experience
